|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
PLoS By Category | Recent
PLoS Articles
|
|
Biochemistry - Biotechnology - Chemistry - Molecular Biology - Oncology - Pharmacology - Physiology
|
Small Molecule-Based Promotion of PKCa-Mediated ß-Catenin Degradation Suppresses the Proliferation of CRT-Positive Cancer Cells
Published:
Friday, October 05, 2012
Author:
Jungsug Gwak et al.
by Jungsug Gwak, Jee-Hyun Lee, Young-Hwa Chung, Gyu-Yong Song, Sangtaek Oh
Aberrant accumulation of intracellular ß-catenin is a well recognized characteristic of several cancers, including prostate, colon, and liver cancers, and is a potential target for development of anticancer therapeutics. Here, we used cell-based small molecule screening to identify CGK062 as an inhibitor of Wnt/ß-catenin signaling. CGK062 promoted protein kinase Ca (PKCa)-mediated phosphorylation of ß-catenin at Ser33/Ser37, marking it for proteasomal degradation. This reduced intracellular ß-catenin levels and consequently antagonized ß-catenin response transcription (CRT). Pharmacological inhibition or depletion of PKCa abrogated CGK062-mediated phosphorylation and degradation of ß-catenin. In addition, CGK062 repressed the expression of the genes encoding cyclin D1, c-myc, and axin-2, ß-catenin target genes, and thus inhibited the growth of CRT-positive cancer cells. Furthermore, treatment of nude mice bearing PC3 xenograft tumors with CGK062 at doses of 50 mg/kg and 100 mg/kg (i.p.) significantly suppressed tumor growth. Our findings suggest that CGK062 exerts its anticancer activity by promoting PKCa-mediated ß-catenin phosphorylation/degradation. Therefore, CGK062 has significant therapeutic potential for the treatment of CRT-positive cancers.
More...
|
|
|
 |
|
|
|
|
|
|
|
|